Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Penpulimab in Adjuvant Hepatocellular Carcinoma
NCT05862337Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, penpulimab in hepatocellular carcinoma (HCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2023; status: recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05862337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862337.